Biotechnology
Janssen Korea Ltd. and Johnson & Johnson Innovation Announce Launch of Seoul Innovation QuickFire Challenge for Healthcare in the New Normal in Collaboration with Seoul Metropolitan Government and Korea Health Industry Development Institute
- QuickFire Challenge calls on innovators to identify and accelerate potential solutions aiming to improve patient care in our post-COVID world. - Awardees will receive up to KRW150,000,000 (approximately US $125,000)[1], residence at the Seoul Bio Hub, and mentorship and coaching from experts at...
2020-07-01 05:30
2775
AGC Biologics Expands Development Capacities for pDNA Services at Heidelberg Site
Expansion will help meet the growing demand for plasmid DNA offerings SEATTLE, June 30, 2020 /PRNewswire/ -- Committed to continuous innovation and expansion of its service offerings, AGC Biologics has announced the expansion of its pDNA Center of Excellence in Heidelberg, Germany. The global bi...
2020-06-30 21:00
2426
Ajinomoto Bio-Pharma Services Introduces AJILITY Fast Track Platform for Drug Product Manufacturing
SAN DIEGO, June 30, 2020 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce the launch of AJILITY™, a flexible and agile drug product manufacturing platform, designed to ...
2020-06-30 20:10
1584
Thrombosis Research Institute (TRI) Announce ETHIC Trial to Evaluate the Potential Benefits of Early Administration of LMWH in Patients with COVID-19
- Clinical trial will recruit approximately 1400 patients in 10 countries starting in July - Participants will be randomised to receive the low molecular weight Heparin enoxaparin or current standard of care for up to 3 weeks from the time of diagnosis - The study is supported through an inve...
2020-06-30 14:00
2000
AOBiome Reports Successful Clinical Trials (Phase 2a in Adults and Phase 1b in Pediatrics) in Pruritus (Itch) Associated with Atopic Dermatitis: Initiates Phase 2b Clinical Trial in Adults
AOBiome's 576 patient Phase 2b trial commences patient enrollment CAMBRIDGE, Massachusetts, June 30, 2020 /PRNewswire/ -- AOBiome Therapeutics, Inc. ("AOBiome"), a leading clinical-stage microbiome company focusing on inflammation, announced initiation of a Phase2b clinical trial in pruritus (i...
2020-06-30 13:00
1184
MedAlliance Gains CE Mark Approval for Coronary SELUTION SLR™ Sirolimus Drug Eluting Balloon
NYON, Switzerland, June 30, 2020 /PRNewswire/ -- MedAlliance has announced the award of its second CE Mark: SELUTION SLR™ 014 PTCA, a novel Sirolimus Drug Eluting Balloon (DEB), for the treatment of coronary arterial disease. This includes indications for both de-novo lesions as well as in-stent ...
2020-06-30 08:00
2298
Global Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2020
Added 18,488 New Subscribers in 4Q20 4Q20 Revenues Increased by 19.2% YoY to RMB299.9 Million ($42.4 Million) 4Q20 Operating Income Increased by 68.1% YoY to RMB149.3 Million ($21.1 Million) Non-GAAP Operating Income Up 58.7% YoY to RMB161.7 Million ($22.8 Million) Conference Call to be Held on Jun...
2020-06-30 04:16
13730
RevImmune Announces Phase II Trial of the T-Cell Growth Factor CYT107 for COVID-19
Under Way in Europe Since May, In Preparation in the U.S. Designated As An Urgent Public Health National Priority In U.K. BETHESDA, Maryland, June 29, 2020 /PRNewswire/ -- RevImmune, a privately held biotechnology company developing CYT107 immune therapy for infectious diseases and cancer, an...
2020-06-29 21:00
2561
Picosun's Medical ALD Solutions Ensure Excellent Hermetic Encapsulation
ESPOO, Finland, June 29, 2020 /PRNewswire/ -- Picosun Group reports excellent results in ALD-organic bilayer encapsulation of metal electrodes for neuroprosthetics and bioelectronic medicine. Group also reports superior hermetic barrier performance of its ALD nanolaminates against corrosive ion ...
2020-06-29 11:34
1332
Philogen Received Clinical Trial Authorisation With Nidlegy in Nonmelanoma Skin Cancer
SIENA, Italy, June 26, 2020 /PRNewswire/ -- Philogen S.p.A., a privately-owned biotechnology company, is pleased to announce that the Swiss national competent authority Swissmedic issued the authorization to run a clinical phase II study in patients with locally advanced, not metastatic nonmelano...
2020-06-26 15:00
1771
ERBA Mannheim Launches CE Marked COVID-19 IgM Antibody ELISA
LONDON, June 25, 2020 /PRNewswire/ -- In response to the ongoing COVID-19 pandemic,Erba Mannheim today launched the ErbaLisa COVID-19 IgM ELISA kit for detection of IgM antibodies to SARS-CoV-2. IgM antibodies are produced first and detectable during disease onset, so using the new assay in comb...
2020-06-25 01:08
3188
Global Cord Blood Corporation to Report Fourth Quarter and Full Year Fiscal 2020 Financial Results
HONG KONG, June 24, 2020 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) (the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that it plans to release financial results fo...
2020-06-24 19:30
14623
Philogen Received Combination Pack Approval for Nidlegy
SIENA, Italy, June 24, 2020 /PRNewswire/ -- Philogen S.p.A., a privately-owned biotechnology company, is pleased to announce that, onJan. 30, 2020, EMA's CHMP expressed a favorable opinion to the request of a combination pack for the to-be-marketed pharmaceutical form of NidlegyTM, a combination ...
2020-06-24 15:00
1302
Akeso Appoints Prof. Bradley Monk as Lead Gynecologic Oncology Advisor and Chair of the Steering Committee
LOS ANGELES, June 24, 2020 /PRNewswire/ -- Akeso, Inc. ("Akeso", 9926.HK) announced the appointment of ProfessorBradley J. Monk, MD, FACOG[1], FACS[2] as Lead Gynecologic Oncology Advisor and Chair of the Steering Committee for its global Phase 2, multicentre registration study to evaluate the ef...
2020-06-24 12:55
7288
InxMed Released Research Data of "FAK inhibitor IN10018 overcomes drug resistance of KRAS G12C inhibition" at 2020 AACR Annual Meeting
SHANGHAI, June 24, 2020 /PRNewswire/ -- InxMed (Shanghai) Co., Ltd. ("InxMed" or "Company"), a clinical stage biotech company dedicated to developing innovative, individualized medicines with international impact, announced that the company has released the research data of "FAK inhibitor IN10018...
2020-06-24 08:41
2194
IgNova Files Patent Application on Antibody Against COVID-19
VISBEK, Germany, June 24, 2020 /PRNewswire/ -- IgNova announced today that it has filed a patent application covering the use of passive immunization to control SARS-CoV-2 infection in humans. IgNova, a biopharmaceutical R&D start up, researches technology based on specific egg immunoglobulins (I...
2020-06-24 02:13
1711
Greater cfDNA Recovery May Help Accelerate Development of Cancer Liquid Biopsy Applications
HONG KONG, June 23, 2020 /PRNewswire/ -- PHASE Scientific, a high-growth biotechnology company that develops innovative sample preparation technologies, announced new findings at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II. The study presented by MD Anderson...
2020-06-23 09:00
2521
Kazia Presents Further Paxalisib and Cantrixil Data at AACR, Reinforcing Positive Efficacy Signals for both Drugs
SYDNEY, June 22, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share poster presentations of interim data from the ongoing phase II study of paxalisib (formerly GDC-0084) in glioblastoma, the most com...
2020-06-22 12:39
4212
Qiming's Portfolio Company SinocellTech Lands on STAR Market
SHANGHAI, June 22, 2020 /PRNewswire/ -- Chinese biologic drug developer SinocellTech, Qiming's portfolio company, today lands on the Science and Technology Innovation Board (the STAR Market). The issue price of SinocellTech (SHSE: 688520) isCNY 25.64 per share. The stock opens at CNY 85 per share...
2020-06-22 12:20
2539
Innovent Announces The Stock Exchange of Hong Kong Limited Approved the "B" Marker Removal from the Company's Stock Symbol in the HKEX
SUZHOU, China, June 22, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announc...
2020-06-22 07:40
6286
Week's Top Stories
Most Reposted
Blackpanda Recognized with Frost & Sullivan's Asia Pacific Company of the Year Award for Incident Response Excellence
[Picked up by 302 media titles]
2025-01-23 09:00
Agoda Expands Its Eco Deals Program Pledging Up to $1.5 Million to Fund Critical Conservation Projects Across 10 Asian Markets in Partnership with WWF
[Picked up by 293 media titles]
2025-01-23 09:00
Star-Studded Sponsor Line-up Takes Centre Court at the Singapore Tennis Open 2025
[Picked up by 291 media titles]
2025-01-28 10:49
Sephora Unveils Its First Film, "Beauty & Belonging" Celebrating Diversity and Authenticity
[Picked up by 288 media titles]
2025-01-24 08:00
Dahua Technology Joins Hands with WWF to Expand Sustainability Efforts Globally
[Picked up by 270 media titles]
2025-01-24 12:15
Most Read
BRI UMKM EXPO(RT) 2025 Returns: Showcasing Local Products to the World
2025-01-25 15:38
7665
U Power Announces Pricing of $5.0 Million Registered Direct Offering
2025-01-24 22:18
5438